Recent Advances in Understanding and Managing Tourette Syndrome

Mary Ann Thenganatt, Joseph Jankovic, Mary Ann Thenganatt, Joseph Jankovic

Abstract

Tourette syndrome (TS) is a neurologic and behavioral disorder consisting of motor and phonic tics with onset in childhood or adolescence. The severity of tics can range from barely perceptible to severely impairing due to social embarrassment, discomfort, self-injury, and interference with daily functioning and school or work performance. In addition to tics, most patients with TS have a variety of behavioral comorbidities, including attention deficit hyperactivity disorder and obsessive-compulsive disorder. Studies evaluating the pathophysiology of tics have pointed towards dysfunction of the cortico-striato-thalamo-cortical circuit, but the mechanism of this hyperkinetic movement disorder is not well understood. Treatment of TS is multidisciplinary, typically involving behavioral therapy, oral medications, and botulinum toxin injections. Deep brain stimulation may be considered for "malignant" TS that is refractory to conventional therapy. In this review, we will highlight recent developments in the understanding and management strategies of TS.

Keywords: Tourette syndrome; behaviour; neurology.

Conflict of interest statement

Competing interests: Dr. Thenganatt has no relevant disclosures. Dr. Jankovic has served as a consultant or as an advisory committee member for Allergan, Inc; Auspex Pharmaceuticals, Inc; Teva Pharmaceutical Industries Ltd.

No competing interests were disclosed.

References

    1. Jankovic J, Gelineau-Kattner R, Davidson A: Tourette's syndrome in adults. Mov Disord. 2010;25(13):2171–2175. 10.1002/mds.23199
    1. Patel N, Jankovic J, Hallett M: Sensory aspects of movement disorders. Lancet Neurol. 2014;13(1):100–112. 10.1016/S1474-4422(13)70213-8
    1. Baizabal-Carvallo JF, Jankovic J: Speech and voice disorders in patients with psychogenic movement disorders. J Neurol. 2015;262(11):2420–2424. 10.1007/s00415-015-7856-7
    1. Thenganatt MA, Jankovic J: Psychogenic movement disorders. Neurol Clin. 2015;33(1):205–224. 10.1016/j.ncl.2014.09.013
    1. Baizabal-Carvallo JF, Jankovic J: The clinical features of psychogenic movement disorders resembling tics. J Neurol Neurosurg Psychiatry. 2014;85(5):573–575. 10.1136/jnnp-2013-305594
    1. Association AP: Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. Arlington, VA: American Psychiatric Publishing;2013. 10.1176/appi.books.9780890425596
    1. Scharf JM, Miller LL, Gauvin CA, et al. : Population prevalence of Tourette syndrome: a systematic review and meta-analysis. Mov Disord. 2015;30(2):221–228. 10.1002/mds.26089

    2. F1000 Recommendation

    1. Hirschtritt ME, Lee PC, Pauls DL, et al. : Lifetime prevalence, age of risk, and genetic relationships of comorbid psychiatric disorders in Tourette syndrome. JAMA psychiatry. 2015;72(4):325–333. 10.1001/jamapsychiatry.2014.2650

    2. F1000 Recommendation

    1. Worbe Y, Lehericy S, Hartmann A: Neuroimaging of tic genesis: Present status and future perspectives. Mov Disord. 2015;30(9):1179–1183. 10.1002/mds.26333
    1. Black KJ, Jankovic J, Hershey T, et al. : Progress in research on Tourette syndrome. J Obsessive Compuls Relat Disord. 2014;3(4):359–362. 10.1016/j.jocrd.2014.03.005
    1. Muellner J, Delmaire C, Valabrégue R, et al. : Altered structure of cortical sulci in gilles de la Tourette syndrome: Further support for abnormal brain development. Mov Disord. 2015;30(5):655–661. 10.1002/mds.26207
    1. Martín-Rodríguez JF, Ruiz-Rodríguez MA, Palomar FJ, et al. : Aberrant cortical associative plasticity associated with severe adult Tourette syndrome. Mov Disord. 2015;30(3):431–435. 10.1002/mds.26151
    1. Suppa A, Marsili L, Di Stasio F, et al. : Cortical and brainstem plasticity in Tourette syndrome and obsessive-compulsive disorder. Mov Disord. 2014;29(12):1523–1531. 10.1002/mds.25960
    1. Worbe Y, Marrakchi-Kacem L, Lecomte S, et al. : Altered structural connectivity of cortico-striato-pallido-thalamic networks in Gilles de la Tourette syndrome. Brain. 2015;138(Pt 2):472–482. 10.1093/brain/awu311

    2. F1000 Recommendation

    1. Yael D, Vinner E, Bar-Gad I: Pathophysiology of tic disorders. Mov Disord. 2015;30(9):1171–1178. 10.1002/mds.26304
    1. Neuner I, Werner CJ, Arrubla J, et al. : Imaging the where and when of tic generation and resting state networks in adult Tourette patients. Front Hum Neurosci. 2014;8:362. 10.3389/fnhum.2014.00362

    2. F1000 Recommendation

    1. Tinaz S, Belluscio BA, Malone P, et al. : Role of the sensorimotor cortex in Tourette syndrome using multimodal imaging. Hum Brain Mapp. 2014;35(12):5834–5846. 10.1002/hbm.22588

    2. F1000 Recommendation

    1. Cheng B, Braass H, Ganos C, et al. : Altered intrahemispheric structural connectivity in Gilles de la Tourette syndrome. Neuroimage Clin. 2014;4:174–181. 10.1016/j.nicl.2013.11.011

    2. F1000 Recommendation

    1. Lerner A, Bagic A, Simmons JM, et al. : Widespread abnormality of the γ-aminobutyric acid-ergic system in Tourette syndrome. Brain. 2012;135(Pt 6):1926–1936. 10.1093/brain/aws104

    2. F1000 Recommendation

    1. Kataoka Y, Kalanithi PS, Grantz H, et al. : Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome. J Comp Neurol. 2010;518(3):277–291. 10.1002/cne.22206

    2. F1000 Recommendation

    1. Tinaz S, Malone P, Hallett M, et al. : Role of the right dorsal anterior insula in the urge to tic in Tourette syndrome. Mov Disord. 2015;30(9):1190–1197. 10.1002/mds.26230

    2. F1000 Recommendation

    1. Hanna PA, Janjua FN, Contant CF, et al. : Bilineal transmission in Tourette syndrome. Neurology. 1999;53(4):813–818. 10.1212/WNL.53.4.813
    1. Pauls DL, Fernandez TV, Mathews CA, et al. : The Inheritance of Tourette Disorder: A review. J Obsessive Compuls Relat Disord. 2014;3(4):380–385. 10.1016/j.jocrd.2014.06.003
    1. Mataix-Cols D, Isomura K, Pérez-Vigil A, et al. : Familial Risks of Tourette Syndrome and Chronic Tic Disorders. A Population-Based Cohort Study. JAMA psychiatry. 2015;72(8):787–793. 10.1001/jamapsychiatry.2015.0627

    2. F1000 Recommendation

    1. Deng H, Gao K, Jankovic J: The genetics of Tourette syndrome. Nat Rev Neurol. 2012;8(4):203–213. 10.1038/nrneurol.2012.26
    1. Ercan-Sencicek AG, Stillman AA, Ghosh AK, et al. : L-histidine decarboxylase and Tourette's syndrome. N Engl J Med. 2010;362(20):1901–1908. 10.1056/NEJMoa0907006
    1. Karagiannidis I, Dehning S, Sandor P, et al. : Support of the histaminergic hypothesis in Tourette syndrome: association of the histamine decarboxylase gene in a large sample of families. J Med Genet. 2013;50(11):760–764. 10.1136/jmedgenet-2013-101637
    1. Scharf JM, Yu D, Mathews CA, et al. : Genome-wide association study of Tourette's syndrome. Mol Psychiatry. 2013;18(6):721–728. 10.1038/mp.2012.69
    1. Paschou P, Yu D, Gerber G, et al. : Genetic association signal near NTN4 in Tourette syndrome. Ann Neurol. 2014;76(2):310–315. 10.1002/ana.24215
    1. McGrath LM, Yu D, Marshall C, et al. : Copy number variation in obsessive-compulsive disorder and Tourette syndrome: a cross-disorder study. J Am Acad Child Adolesc Psychiatry. 2014;53(8):910–919. 10.1016/j.jaac.2014.04.022
    1. Yu D, Mathews CA, Scharf JM, et al. : Cross-disorder genome-wide analyses suggest a complex genetic relationship between Tourette's syndrome and OCD. Am J Psychiatry. 2015;172(1):82–93. 10.1176/appi.ajp.2014.13101306
    1. Albin RL, Koeppe RA, Wernette K, et al. : Striatal [ 11C]dihydrotetrabenazine and [ 11C]methylphenidate binding in Tourette syndrome. Neurology. 2009;72(16):1390–1396. 10.1212/WNL.0b013e3181a187dd
    1. Termine C, Selvini C, Rossi G, et al. : Emerging treatment strategies in Tourette syndrome: what's in the pipeline? Int Rev Neurobiol. 2013;112:445–480. 10.1016/B978-0-12-411546-0.00015-9
    1. Jankovic J: Therapeutic developments for tics and myoclonus. Mov Disord. 2015;30(11):1566–1573. 10.1002/mds.26414
    1. Mogwitz S, Buse J, Ehrlich S, et al. : Clinical pharmacology of dopamine-modulating agents in Tourette's syndrome. Int Rev Neurobiol. 2013;112:281–349. 10.1016/B978-0-12-411546-0.00010-X
    1. Wijemanne S, Wu LJ, Jankovic J: Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord. 2014;29(1):126–130. 10.1002/mds.25692
    1. Weisman H, Qureshi IA, Leckman JF, et al. : Systematic review: pharmacological treatment of tic disorders--efficacy of antipsychotic and alpha-2 adrenergic agonist agents. Neurosci Biobehav Rev. 2013;37(6):1162–1171. 10.1016/j.neubiorev.2012.09.008

    2. F1000 Recommendation

    1. Wenzel C, Kleimann A, Bokemeyer S, et al. : Aripiprazole for the treatment of Tourette syndrome: a case series of 100 patients. J Clin Psychopharmacol. 2012;32(4):548–550. 10.1097/JCP.0b013e31825ac2cb
    1. Yoo HK, Joung YS, Lee JS, et al. : A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder. J Clin Psychiatry. 2013;74(8):e772–80. 10.4088/JCP.12m08189
    1. Zheng W, Li XB, Xiang YQ, et al. : Aripiprazole for Tourette's syndrome: a systematic review and meta-analysis. Hum Psychopharmacol. 2016;31(1):11–8. 10.1002/hup.2498
    1. Peña MS, Yaltho TC, Jankovic J: Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord. 2011;26(1):147–152. 10.1002/mds.23402
    1. Gilbert DL, Budman CL, Singer HS, et al. : A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome. Clin Neuropharmacol. 2014;37(1):26–30. 10.1097/WNF.0000000000000017

    2. F1000 Recommendation

    1. Kenney C, Hunter C, Jankovic J: Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007;22(2):193–197. 10.1002/mds.21222
    1. Chen JJ, Ondo WG, Dashtipour K, et al. : Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther. 2012;34(7):1487–1504. 10.1016/j.clinthera.2012.06.010
    1. Porta M, Sassi M, Cavallazzi M, et al. : Tourette's syndrome and role of tetrabenazine: review and personal experience. Clin Drug Investig. 2008;28(7):443–459. 10.2165/00044011-200828070-00006

    2. F1000 Recommendation

    1. Kenney C, Hunter C, Mejia N, et al. : Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol. 2006;29(5):259–264. 10.1097/01.WNF.0000228369.25593.35
    1. Jankovic J, Clarence-Smith K: Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011;11(11):1509–1523. 10.1586/ern.11.149
    1. Cavanna AE, Nani A: Antiepileptic drugs and Tourette syndrome. Int Rev Neurobiol. 2013;112:373–389. 10.1016/B978-0-12-411546-0.00012-3
    1. Yang CS, Zhang LL, Zeng LN, et al. : Topiramate for Tourette's syndrome in children: a meta-analysis. Pediatr Neurol. 2013;49(5):344–350. 10.1016/j.pediatrneurol.2013.05.002
    1. Jankovic J, Jimenez-Shahed J, Brown LW: A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010;81(1):70–73. 10.1136/jnnp.2009.185348

    2. F1000 Recommendation

    1. Persaud R, Garas G, Silva S, et al. : An evidence-based review of botulinum toxin (Botox) applications in non-cosmetic head and neck conditions. JRSM Short Rep. 2013;4(2):10. 10.1177/2042533312472115

    2. F1000 Recommendation

    1. Kwak CH, Hanna PA, Jankovic J: Botulinum toxin in the treatment of tics. Arch Neurol. 2000;57(8):1190–1193. 10.1001/archneur.57.8.1190
    1. Marras C, Andrews D, Sime E, et al. : Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology. 2001;56(5):605–610. 10.1212/WNL.56.5.605

    2. F1000 Recommendation

    1. Porta M, Maggioni G, Ottaviani F, et al. : Treatment of phonic tics in patients with Tourette's syndrome using botulinum toxin type A. Neurol Sci. 2004;24(6):420–423. 10.1007/s10072-003-0201-4

    2. F1000 Recommendation

    1. Cheung MY, Shahed J, Jankovic J: Malignant Tourette syndrome. Mov Disord. 2007;22(12):1743–1750. 10.1002/mds.21599
    1. Whiting PF, Wolff RF, Deshpande S, et al. : Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456–2473. 10.1001/jama.2015.6358
    1. Müller-Vahl KR: Treatment of Tourette syndrome with cannabinoids. Behav Neurol. 2013;27(1):119–124. 10.3233/BEN-120276
    1. Kluger B, Triolo P, Jones W, et al. : The therapeutic potential of cannabinoids for movement disorders. Mov Disord. 2015;30(3):313–327. 10.1002/mds.26142
    1. Curtis A, Clarke CE, Rickards HE: Cannabinoids for Tourette's Syndrome. Cochrane Database Syst Rev. 2009; (4):CD006565. 10.1002/14651858.CD006565.pub2

    2. F1000 Recommendation

    1. Piacentini J, Woods DW, Scahill L, et al. : Behavior therapy for children with Tourette disorder: a randomized controlled trial. JAMA. 2010;303(19):1929–1937. 10.1001/jama.2010.607

    2. F1000 Recommendation

    1. Wilhelm S, Peterson AL, Piacentini J, et al. : Randomized trial of behavior therapy for adults with Tourette syndrome. Arch Gen Psychiatry. 2012;69(8):795–803. 10.1001/archgenpsychiatry.2011.1528

    2. F1000 Recommendation

    1. McGuire JF, Piacentini J, Brennan EA, et al. : A meta-analysis of behavior therapy for Tourette Syndrome. J Psychiatr Res. 2014;50:106–112. 10.1016/j.jpsychires.2013.12.009

    2. F1000 Recommendation

    1. Scahill L, Woods DW, Himle MB, et al. : Current controversies on the role of behavior therapy in Tourette syndrome. Mov Disord. 2013;28(9):1179–1183. 10.1002/mds.25488
    1. Zhang JG, Ge Y, Stead M, et al. : Long-term outcome of globus pallidus internus deep brain stimulation in patients with Tourette syndrome. Mayo Clin Proc. 2014;89(11):1506–1514. 10.1016/j.mayocp.2014.05.019

    2. F1000 Recommendation

    1. Servello D, Zekaj E, Saleh C, et al. : Deep Brain Stimulation in Gilles de la Tourette Syndrome: What Does the Future Hold? A Cohort of 48 Patients. Neurosurgery. 2016;78(1):91–100. 10.1227/NEU.0000000000001004

    2. F1000 Recommendation

    1. Kefalopoulou Z, Zrinzo L, Jahanshahi M, et al. : Bilateral globus pallidus stimulation for severe Tourette's syndrome: a double-blind, randomised crossover trial. Lancet Neurol. 2015;14(6):595–605. 10.1016/S1474-4422(15)00008-3

    2. F1000 Recommendation

    1. Fraint A, Pal G: Deep Brain Stimulation in Tourette's Syndrome. Front Neurol. 2015;6:170. 10.3389/fneur.2015.00170
    1. Servello D, Sassi M, Gaeta M, et al. : Tourette syndrome (TS) bears a higher rate of inflammatory complications at the implanted hardware in deep brain stimulation (DBS). Acta Neurochir (Wien). 2011;153(3):629–632. 10.1007/s00701-010-0851-y
    1. Okun MS, Foote KD, Wu SS, et al. : A trial of scheduled deep brain stimulation for Tourette syndrome: moving away from continuous deep brain stimulation paradigms. JAMA Neurol. 2013;70(1):85–94. 10.1001/jamaneurol.2013.580

    2. F1000 Recommendation

    1. Almeida L, Martinez-Ramirez D, Rossi PJ, et al. : Chasing tics in the human brain: development of open, scheduled and closed loop responsive approaches to deep brain stimulation for Tourette syndrome. J Clin Neurol. 2015;11(2):122–131. 10.3988/jcn.2015.11.2.122
    1. Schrock LE, Mink JW, Woods DW, et al. : Tourette syndrome deep brain stimulation: a review and updated recommendations. Mov Disord. 2015;30(4):448–471. 10.1002/mds.26094
    1. Viswanathan A, Jimenez-Shahed J, Baizabal Carvallo JF, et al. : Deep brain stimulation for Tourette syndrome: target selection. Stereotact Funct Neurosurg. 2012;90(4):213–224. 10.1159/000337776
    1. Jimenez-Shahed J: Design challenges for stimulation trials of Tourette's syndrome. Lancet Neurol. 2015;14(6):563–565. 10.1016/S1474-4422(15)00043-5
    1. Gilbert DL, Jankovic J: Pharmacological treatment of Tourette syndrome. J Obsessive Compuls Relat Disord. 2014;3(4):407–414. 10.1016/j.jocrd.2014.04.006

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi